Cargando…
Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
BACKGROUND: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades. METHODS: Serological tests were performed according to standard procedures. Detection of d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678312/ https://www.ncbi.nlm.nih.gov/pubmed/26696803 http://dx.doi.org/10.1159/000440673 |
_version_ | 1782405433574555648 |
---|---|
author | Mayer, Beate Bartolmäs, Thilo Yürek, Salih Salama, Abdulgabar |
author_facet | Mayer, Beate Bartolmäs, Thilo Yürek, Salih Salama, Abdulgabar |
author_sort | Mayer, Beate |
collection | PubMed |
description | BACKGROUND: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades. METHODS: Serological tests were performed according to standard procedures. Detection of drug-dependent antibodies was performed in the presence and absence of the relevant drug and/or their ex vivo antigens. RESULTS: Over the last 20 years, 73 patients have been identified with DIHA in our institute, which was related to 15 different drugs. The most common single drugs identified were diclofenac (n = 23), piperacillin (n = 13), ceftriaxone (n = 12) and oxaliplatin (n = 10). As far as data were available, haemolysis was acute in all patients, and signs of intravascular haemolysis were present in 90% of the cases. Haemolysis resulted in death in 17 patients (23%). The remaining patients recovered, but haemolysis was complicated by transitory renal and/or liver failure or shock in 11 patients. Upon initial evaluation, the antibody screening test was positive in 36 cases. A positive direct antiglobulin test (DAT) at least with anti-C3d was found in 65 cases, with anti-IgG only in 6 cases, and with anti-IgA only in 1 case. CONCLUSION: DIHA is a rare but potentially life-threatening disorder that should be considered if a patient develops haemolysis under drug treatment. The main serological finding is a positive DAT, primarily with anti-C3d. |
format | Online Article Text |
id | pubmed-4678312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-46783122015-12-22 Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre Mayer, Beate Bartolmäs, Thilo Yürek, Salih Salama, Abdulgabar Transfus Med Hemother Original Article BACKGROUND: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades. METHODS: Serological tests were performed according to standard procedures. Detection of drug-dependent antibodies was performed in the presence and absence of the relevant drug and/or their ex vivo antigens. RESULTS: Over the last 20 years, 73 patients have been identified with DIHA in our institute, which was related to 15 different drugs. The most common single drugs identified were diclofenac (n = 23), piperacillin (n = 13), ceftriaxone (n = 12) and oxaliplatin (n = 10). As far as data were available, haemolysis was acute in all patients, and signs of intravascular haemolysis were present in 90% of the cases. Haemolysis resulted in death in 17 patients (23%). The remaining patients recovered, but haemolysis was complicated by transitory renal and/or liver failure or shock in 11 patients. Upon initial evaluation, the antibody screening test was positive in 36 cases. A positive direct antiglobulin test (DAT) at least with anti-C3d was found in 65 cases, with anti-IgG only in 6 cases, and with anti-IgA only in 1 case. CONCLUSION: DIHA is a rare but potentially life-threatening disorder that should be considered if a patient develops haemolysis under drug treatment. The main serological finding is a positive DAT, primarily with anti-C3d. S. Karger AG 2015-09 2015-09-09 /pmc/articles/PMC4678312/ /pubmed/26696803 http://dx.doi.org/10.1159/000440673 Text en Copyright © 2015 by S. Karger GmbH, Freiburg http://www.karger.com/Authors_Choice This is an open access article distributed under the terms of Karger's Author's Choice™ licensing agreement, adapted from the Creative Commons Attribution Non-Commercial 2.5 license. This license allows authors to re-use their articles for educational and research purposes as long as the author and the journal are fully acknowledged. |
spellingShingle | Original Article Mayer, Beate Bartolmäs, Thilo Yürek, Salih Salama, Abdulgabar Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre |
title | Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre |
title_full | Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre |
title_fullStr | Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre |
title_full_unstemmed | Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre |
title_short | Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre |
title_sort | variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678312/ https://www.ncbi.nlm.nih.gov/pubmed/26696803 http://dx.doi.org/10.1159/000440673 |
work_keys_str_mv | AT mayerbeate variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre AT bartolmasthilo variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre AT yureksalih variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre AT salamaabdulgabar variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre |